Latest Comments

Could Novartis’ longer-acting anti-VEGF Drug, RTH258, offset Lucentis’ loss to Eylea?

Could Novartis’ longer-acting anti-VEGF Drug, RTH258, offset Lucentis’ loss to Eylea?

Fecal transplant-based treatment for C. difficile reaches phase III trials

Fecal transplant-based treatment for C. difficile reaches phase III trials

Unpredictable epidemiology necessitates a more empirical approach to Zika and Ebola vaccine development

Unpredictable epidemiology necessitates a more empirical approach to Zika and Ebola vaccine development

Highlights from the 2017 ATS Conference – Positive results for Nucala marks strong potential for GSK to win the first approved biologic for eGPA

Highlights from the 2017 ATS Conference – Positive results for Nucala marks strong potential for GSK to win the first approved biologic for eGPA

Majority of UC Cases Considered Mild to Moderate

Majority of UC Cases Considered Mild to Moderate

Generic antibiotics are more important than ever, but supply shortages threaten their usefulness

Generic antibiotics are more important than ever, but supply shortages threaten their usefulness

Carcinoma Remains Predominant Histologic Subtype of Ovarian Cancer

Carcinoma Remains Predominant Histologic Subtype of Ovarian Cancer

EMA withdrawal threatens UK patient access to cutting edge therapies

EMA withdrawal threatens UK patient access to cutting edge therapies

AbbVie impresses with solid clinical data for its newest DAA regimen

AbbVie impresses with solid clinical data for its newest DAA regimen

Trulance sNDA submission for IBS-C: a step forward for Synergy Pharmaceuticals

Trulance sNDA submission for IBS-C: a step forward for Synergy Pharmaceuticals

Rethinking future treatment options for sepsis: from immunosuppressive to immunostimulating drugs

Rethinking future treatment options for sepsis: from immunosuppressive to immunostimulating drugs

PTC Therapeutics' Translarna fails phase III trial for cystic fibrosis

PTC Therapeutics' Translarna fails phase III trial for cystic fibrosis

J&J’s guselkumab leads the race for first to market IL-23 inhibitor for psoriasis

J&J’s guselkumab leads the race for first to market IL-23 inhibitor for psoriasis

A new age of drug development in atopic dermatitis

A new age of drug development in atopic dermatitis

The importance of real world evidence in the 21st Century Cures Act

The importance of real world evidence in the 21st Century Cures Act

Hold on clinical trials of Vadastuximab Talirine may be temporary setback

Hold on clinical trials of Vadastuximab Talirine may be temporary setback

Intarcia Therapeutics' game-changing type 2 diabetes treatment is on the horizon

Intarcia Therapeutics' game-changing type 2 diabetes treatment is on the horizon

SIMPLIFY Results Complicate Gilead's Entry into the Myelofibrosis Market

SIMPLIFY Results Complicate Gilead's Entry into the Myelofibrosis Market